
Coral Laboratories Ltd. — Investor Relations & Filings
Coral Laboratories Ltd. specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The product portfolio encompasses various dosage forms, including tablets, capsules, oral liquids, external preparations such as creams and ointments, and sterile injectables. These offerings address multiple therapeutic areas, including anti-bacterial, analgesic, anti-inflammatory, and gastrointestinal health. The company operates manufacturing facilities that adhere to WHO-GMP standards, ensuring rigorous quality management and compliance with global regulatory requirements. With a focus on providing accessible healthcare solutions, the organization serves a broad client base across domestic and international markets. Research and development efforts are centered on formulation optimization and the expansion of the product pipeline to meet evolving medical needs.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Final dividend of ? 2 per share | 2026-05-30 | English | |
| Appointment of Cost Auditor | 2026-05-30 | English | |
| Appointment of Internal Auditor | 2026-05-30 | English | |
| The Board has approved ? 2 per share dividend. | 2026-05-30 | English | |
| Results for the financial year ended on March 31, 2026 | 2026-05-30 | English | |
| Outcome of Board meeting held on May 30, 2026 | 2026-05-30 | English |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
9 filings
| |||||
| 47903331 | Final dividend of ? 2 per share | 2026-05-30 | English | ||
| 47903382 | Appointment of Cost Auditor | 2026-05-30 | English | ||
| 47903391 | Appointment of Internal Auditor | 2026-05-30 | English | ||
| 47902928 | The Board has approved ? 2 per share dividend. | 2026-05-30 | English | ||
| 47902956 | Results for the financial year ended on March 31, 2026 | 2026-05-30 | English | ||
| 47902993 | Outcome of Board meeting held on May 30, 2026 | 2026-05-30 | English | ||
| 47899294 | Annua Secretarial Compliance Report for the financial year ended March 31, 2026 | 2026-05-30 | English | ||
| 46583880 | Board to consider Dividend | 2026-05-20 | English | ||
| 46582721 | Coral Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Pursuant to Regulation 29 .... | 2026-05-20 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ANHUI FENGYUAN PHARMACEUTICAL CO., LTD
Produces injections, solid dosage forms, APIs, and nutritio…
|
000153 | CN | Manufacturing |
|
Anhui Huangshan Capsule Co.,Ltd
Produces empty hard capsules, including gelatin and HPMC ve…
|
002817 | CN | Manufacturing |
|
Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
Develops and manufactures pharmaceutical excipients for sol…
|
300452 | CN | Manufacturing |
|
Anika Therapeutics, Inc.
A global joint preservation company developing solutions fo…
|
ANIK | US | Manufacturing |
|
ANIMALCARE GROUP PLC
Develops and commercializes veterinary pharmaceutical produ…
|
ANCR | GB | Manufacturing |
|
ANI PHARMACEUTICALS INC
Develops, manufactures, and markets branded, generic, and O…
|
ANIP | US | Manufacturing |
|
ANLON HEALTHCARE LIMITED
Researches and manufactures APIs, intermediates, and finish…
|
AHCL | IN | Manufacturing |
|
Annexin Pharmaceuticals AB
Clinical-stage biotech developing a cell-protecting biologi…
|
ANNX | SE | Manufacturing |
|
Annexon, Inc.
Clinical-stage biopharma developing complement medicines by…
|
ANNX | US | Manufacturing |
|
Antengene Corporation Limited
Global biopharma developing and commercializing novel oncol…
|
6996 | KY | Manufacturing |
Coral Laboratories Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/61976/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=61976 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=61976 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=61976 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 61976}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Coral Laboratories Ltd. (id: 61976)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.